Jefferies upgrades Expedia stock rating on growth outlook By Investing.com

Jefferies upgraded Expedia to Buy and raised its price target to $300 from $240, citing high single-digit lodging bookings growth, 100+ bps annual EBITDA margin expansion and a three-plus year runway of 20%+ EPS growth; the $300 PT implies ~14x 2027 GAAP P/E vs a current P/E of 23. Expedia reported Q4 B2B revenue up 24% YoY and accelerating B2C lodging/traffic; Morgan Stanley raised its PT to $290 (Equalweight) while DA Davidson cut its PT to $260 and Bernstein kept $256 (Market Perform). Jefferies noted Middle East headline risk and congressional scrutiny over surveillance pricing algorithms, and AI disruption concerns have weighed on travel stocks.

Analysis

The OTA landscape is bifurcating: vendors that scale distribution and lock inventory with low incremental cost will compound margins faster than purely consumer-facing channels. Growth driven by channel diversification (B2B/wholesale) tends to shift working capital and counterparty exposure toward travel suppliers and corporate clients, increasing sensitivity to receivable cycles and credit conditions during downturns. Meanwhile, price-discovery intermediaries (metasearch, payment processors, hotel channel managers) will capture a larger share of the incremental margin pool unless the OTA can materially improve direct-conversion economics.

Regulatory and AI risks are asymmetric and front-loaded. Congressional or antitrust action that limits algorithmic pricing or enforces transparency can compress yield quickly — effects would show in 1–3 quarters through both lost pricing power and increased compliance costs. Separately, AI-enabled disintermediation (dynamic packaging by suppliers, smarter metasearch) is a 12–36 month secular threat that can accelerate margin erosion if not countered by product investment or exclusive supply agreements.

These dynamics create a bifurcated trade set: capital-allocation and execution winners will rerate, but headline shocks (geopolitics, hearings) can produce sharp drawdowns. The optimal exposures are asymmetric — own a convex, hedged position into short-term regulatory/geopolitical windows while keeping a longer-duration barbell for upside from multiple re-rating catalysts (cost-outs, share consolidation, superior B2B execution). Monitor receivables days, buyback cadence, and any regulatory filings as high-frequency indicators of risk appetite and optionality monetization.

Key Decisions for Investors

• Long EXPE shares (6–12 month horizon), 2–4% NAV position size. Entry on a pullback of 8–12% off recent highs; target asymmetric upside (~25–40%) vs a tactical downside of ~12–15% if travel demand or regulatory headlines deteriorate. Hedge with 3–6 month puts sized to cover 50% of notional to limit headline risk.
• Pair trade: long EXPE / short BKNG (equal-dollar) for 6–12 months to play execution and margin convergence. Rationale: capture idiosyncratic operational upside in EXPE while neutralizing macro travel demand exposure; cut pair if spread narrows <5% or after next two earnings beats/misses.
• Options idea (lower cost, defined risk): buy EXPE 9–12 month call spreads (buy 12–18 month OTM call, sell further OTM call) sized to 1–2% NAV; expected payoff skewed to a multi-quarter margin/catalyst re-rating. Use as replacement for outright stock to limit downside on geopolitical/regulatory shocks.
• Event hedge: buy short-dated (1–3 month) EXPE puts or a collar ahead of any announced regulatory hearing or earnings if calendar shows near-term event; treat as insurance — aim to pay <2% premium of NAV for 6–8% downside protection over the event window.